NeOnc’s Intranasal NEO100 Trial Marks a New Step in Pediatric Brain Tumor Investing

NeOnc Technologies Holdings, Inc. (NTHI) announced an update on their ongoing clinical study.

Study Overview

NeOnc Technologies Holdings, Inc. (NTHI), through Neonc Technologies, Inc., is launching a Phase 1b study titled “An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain Tumors.” The main goal is to test how safe NEO100 is in children and young patients with aggressive brain tumors, to find a workable dose range, and to confirm that the drug reaches brain tumors when given through the nose. This early-stage effort matters because it targets high-need cancers where current options are limited, and any positive signal could help shape the future value of NeOnc’s pipeline.

Intervention/Treatment

The study tests NEO100, a drug based on a purified form of a naturally occurring compound called perillyl alcohol. It is delivered as a liquid solution sprayed into the nose. The aim is to use this direct route to get the drug into the brain, try to reach tumors more effectively, and do so without invasive procedures, which is especially important in a pediatric setting.

Study Design

This is an interventional Phase 1 trial with a single treatment group. All enrolled patients receive intranasal NEO100; there is no placebo or comparison arm. The trial is “open label,” meaning doctors and patients know what is being given, and there is no blinding. Doses will be increased in steps across small patient groups to understand safety, side effects, and how much drug can be given while still being tolerable, with the main goal being treatment, not just observation.

Study Timeline

The study was first submitted to the registry on March 13, 2024, signaling the formal planning and regulatory preparation phase. It is currently listed as “Not Yet Recruiting,” indicating that site setup and approvals are still in progress. The latest update to the trial record was posted on January 13, 2026, suggesting recent sponsor activity and continued commitment to the program. Primary and final completion dates have not yet been posted, which is typical for an early-stage, dose-finding trial still approaching first-patient enrollment.

Market Implications

For investors, this update reinforces NeOnc’s push into pediatric brain cancers with a differentiated intranasal approach, a niche where there are few effective treatments and high unmet need. While Phase 1b data will focus on safety and dosing rather than clear survival outcomes, any early hint that NEO100 safely reaches tumors and shows manageable side effects can support a more favorable risk profile, making it easier to raise capital or attract partners. In a competitive oncology field dominated by larger players in adult brain tumors and immunotherapy, NeOnc’s pediatric focus may help it stand out, but timelines remain long and clinical risk is high. Overall, the fresh trial update can support cautious optimism and speculative interest, but it is unlikely on its own to drive sustained valuation changes without follow-up data readouts.

The study is ongoing in setup and has been recently updated, with further details available on the ClinicalTrials.gov portal under the NCT06357377 identifier.

To learn more about NTHI’s potential, visit the NeOnc Technologies Holdings, Inc. drug pipeline page.